atogepant
Selected indexed studies
- Atogepant for the Preventive Treatment of Migraine. (N Engl J Med, 2021) [PMID:34407343]
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37516125]
- Atogepant. (, 2006) [PMID:36153941]
_Worker-drafted node — pending editorial review._
Connections
atogepant is a side effect of
Sources
- Atogepant for the Preventive Treatment of Migraine. (2021) pubmed
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Atogepant. (2006) pubmed
- Atogepant. (2012) pubmed
- Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. (2024) pubmed
- Atogepant: First Approval. (2022) pubmed
- Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. (2024) pubmed
- Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. (2024) pubmed
- PMID:40073182 (2024) pubmed
- Atogepant for the prevention of episodic migraine in adults. (2022) pubmed